Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
762.980.17%
QQQ
722.050.08%
BTC/USD
81097.750.1585%
DIA
516.150.05%
GLD
401.490.08%
TLT
81.260.01%

AbCellera Biologics Inc (ABCL) Stock Price, Quote, News & History

ABCLNASDAQ
Trade with Public
Trade with Public
$12.63
-0.1-0.79%
At close: Sep 18, 5:00 PM EST
$12.70
0.06860.54%
After Hours: Sep 18, 7:59 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

AbCellera Biologics (ABCL) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$12.73
Close
$12.63
Volume / Avg.
5.44M / 7.45M
Day Range
$12.37 - $12.96
52 Wk Range
2.75 - 13.18
Market Cap
$4.11B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
67
Short Interest
13.67%
Days to Cover
5.18

Recent AbCellera Biologics Inc. News

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Vandana Singh

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Avi Kapoor

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.
Vandana Singh

National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.
Avi Kapoor

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.
Vandana Singh

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-94.94M
Investing Cash Flow (TTM)
97.89M
Financing Cash Flow (TTM)
25.07M
Free Cash Flow (TTM)
-119.67M
Capital Expenditure (TTM)
-24.73M
Net Change in Cash (TTM)
28.02M

Analyst Trends and Forecast

1
Apr
1
May
1
Jul
3
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$3.69B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
58.06
PB Ratio (TTM)
4.60
Earnings Yield % (TTM)
-4.24%
Earnings Yield % (FWD)
-
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$2.77

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$120.07M
Debt to Equity
0.15
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$12.73
Close
$12.63
Volume / Avg.
5.44M / 7.45M
Day Range
$12.37 - $12.96
52 Wk Range
2.75 - 13.18
Market Cap
$4.11B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
67
Short Interest
13.67%
Days to Cover
5.18

About

Sector
Health Care
Industry
Life Sciences Tools & Services
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that ...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy AbCellera Biologics (ABCL) stock?

A

You can purchase shares of AbCellera Biologics (NASDAQ:ABCL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are AbCellera Biologics (ABCL) competitors?

Q

What is the forecast, or price target, for AbCellera Biologics (ABCL) stock?

A

AbCellera Biologics has a consensus price target of $13.00.

Q

What is the current price for AbCellera Biologics (ABCL)?

A

The stock price for AbCellera Biologics (NASDAQ: ABCL) is $12.6986 last updated September 18, 2026 at 7:59 PM EDT.

Q

Does AbCellera Biologics (ABCL) pay a dividend?

A

There are no upcoming dividends for AbCellera Biologics.

Q

When is AbCellera Biologics (NASDAQ:ABCL) reporting earnings?

A

AbCellera Biologics does not have any upcoming earnings scheduled.

Q

Is AbCellera Biologics (ABCL) going to split?

A

There is no upcoming split for AbCellera Biologics.

Q

What sector and industry does AbCellera Biologics (ABCL) operate in?

A

AbCellera Biologics is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved